Joshua Saef
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joshua Saef has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Wai Hong Wilson Tang
Cleveland Clinic
4 shared publications - Ari Cedars
Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD
3 shared publications Jong Mi Ko
Division of Cardiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas
2 shared publications- Kamila S. White
University of Missouri-St. Louis
2 shared publications - Lauren Ives
Cleveland Clinic Foundation
2 shared publications - Mazen Hanna
Cleveland Clinic, Cleveland, USA
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (45)
Recovery of Postpartum Ventricular Dysfunction in a Fontan Patient Treated With Guideline-Directed Medical Therapy
- 11 November 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (45)
Open AccessRecovery of Postpartum Ventricular Dysfunction in a Fontan Patient Treated With Guideline-Directed Medical Therapy
- Open Access
- 27 October 2026
- Published by Elsevier in JACC: Case Reports
Salvage Transcatheter Mitral Valve-in-Valve With Aspiration Thrombectomy in a Young Adult With Repaired CHD
- 27 October 2026
- Published by Elsevier in JACC: Case Reports
Open AccessSalvage Transcatheter Mitral Valve-in-Valve With Aspiration Thrombectomy in a Young Adult With Repaired CHD
- Open Access
- 27 October 2026
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
Navigating the Road to Specialization in Adult Congenital Heart Disease
Adult congenital heart disease (ACHD) has evolved from a pediatric-focused field to a growing adult cardiovascular subspecialty, driven by advances in surgery and medical therapy that now allow nearly 2 million adults in the United States to live with congenital heart disease. Despite these advances, an estimated workforce of board-certified ACHD cardiologists remains insufficient for the growing patient population, underscoring a continued mismatch between workforce needs and the trainee pipeline. This manuscript reviews contemporary pathways to ACHD sub-specialization, including a combined internal medicine and pediatrics (‘Med-Peds’) residency followed by adult or pediatric cardiology, internal medicine followed by adult cardiology, and pediatrics followed by pediatric cardiology, each culminating in dedicated ACHD fellowship. For each route, the article outlines key strengths, limitations, and typical curricular emphases, and describes how Accreditation Council for Graduate Medical Education-recommended clinical blocks can be tailored to remediate background-specific gaps while preserving a common competency-based endpoint. By clarifying training structures, expectations, and career implications, this work seeks to demystify the pathway to ACHD cardiology and encourage workforce interest in caring for this rapidly growing, high-need population.
- 27 October 2026
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
Open AccessNavigating the Road to Specialization in Adult Congenital Heart Disease
Adult congenital heart disease (ACHD) has evolved from a pediatric-focused field to a growing adult cardiovascular subspecialty, driven by advances in surgery and medical therapy that now allow nearly 2 million adults in the United States to live with congenital heart disease. Despite these advances, an estimated workforce of board-certified ACHD cardiologists remains insufficient for the growing patient population, underscoring a continued mismatch between workforce needs and the trainee pipeline. This manuscript reviews contemporary pathways to ACHD sub-specialization, including a combined internal medicine and pediatrics (‘Med-Peds’) residency followed by adult or pediatric cardiology, internal medicine followed by adult cardiology, and pediatrics followed by pediatric cardiology, each culminating in dedicated ACHD fellowship. For each route, the article outlines key strengths, limitations, and typical curricular emphases, and describes how Accreditation Council for Graduate Medical Education-recommended clinical blocks can be tailored to remediate background-specific gaps while preserving a common competency-based endpoint. By clarifying training structures, expectations, and career implications, this work seeks to demystify the pathway to ACHD cardiology and encourage workforce interest in caring for this rapidly growing, high-need population.
- Open Access
- 6 August 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (39)
Expanding Access to Specialized Adult Congenital Heart Disease Care Using a Hub-and-Spoke Model of Care
- 6 August 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (39)
Open AccessExpanding Access to Specialized Adult Congenital Heart Disease Care Using a Hub-and-Spoke Model of Care
- Open Access
Managing High Risk Pregnancy in Single Ventricle Physiology with Acquired von Willebrand Disease: A Case Report
Background and Clinical Significance: Left ventricular hypoplasia is often repaired surgically in sequence to a Fontan circulation, which is a physiologic state that presents unique challenges during pregnancy. Although women with Fontan physiology can achieve successful pregnancy outcomes, they remain at elevated risk for cardiac, thrombotic, and obstetric complications. Case Presentation: We describe a 38-year-old woman with Fontan physiology and acquired von Willebrand syndrome (AVWS) who was admitted at 23 weeks gestation for preterm premature rupture of membranes. The patient had history of prior classical cesarean delivery and two previous miscarriages. Her pregnancy was further complicated by abnormal placental vasculature and uterine arteriovenous malformation. Given her bleeding diathesis, hematology advised against anticoagulation or antiplatelet therapy, and she ultimately underwent a successful low transverse cesarean delivery under general anesthesia at 24 weeks. Postpartum hemorrhage was managed with clotting factor replacement and supportive care. Conclusions: This case illustrates how AVWS may mitigate thrombotic risk in Fontan physiology and how early activation of a cardio-obstetrics team can enable tailored planning. As more patients with complex congenital heart disease reach reproductive age, multidisciplinary coordination, shared infrastructure, and individualized birth plans will be essential to achieving optimal maternal–fetal outcomes.
Open AccessManaging High Risk Pregnancy in Single Ventricle Physiology with Acquired von Willebrand Disease: A Case Report
Background and Clinical Significance: Left ventricular hypoplasia is often repaired surgically in sequence to a Fontan circulation, which is a physiologic state that presents unique challenges during pregnancy. Although women with Fontan physiology can achieve successful pregnancy outcomes, they remain at elevated risk for cardiac, thrombotic, and obstetric complications. Case Presentation: We describe a 38-year-old woman with Fontan physiology and acquired von Willebrand syndrome (AVWS) who was admitted at 23 weeks gestation for preterm premature rupture of membranes. The patient had history of prior classical cesarean delivery and two previous miscarriages. Her pregnancy was further complicated by abnormal placental vasculature and uterine arteriovenous malformation. Given her bleeding diathesis, hematology advised against anticoagulation or antiplatelet therapy, and she ultimately underwent a successful low transverse cesarean delivery under general anesthesia at 24 weeks. Postpartum hemorrhage was managed with clotting factor replacement and supportive care. Conclusions: This case illustrates how AVWS may mitigate thrombotic risk in Fontan physiology and how early activation of a cardio-obstetrics team can enable tailored planning. As more patients with complex congenital heart disease reach reproductive age, multidisciplinary coordination, shared infrastructure, and individualized birth plans will be essential to achieving optimal maternal–fetal outcomes.
- Open Access
- 12 June 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (7) , 103577
Dual-Phase Increase in Atrial Arrhythmia Prevalence Following Percutaneous Atrial Septal Defect Closure
- 12 June 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (7) , 103577
Open AccessDual-Phase Increase in Atrial Arrhythmia Prevalence Following Percutaneous Atrial Septal Defect Closure
- 5 November 2024
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 27 (1) , 1-11
Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies
Purpose of the Review The need for treatments and specialists to manage complications that adults with congenital heart disease experience with heart failure is pressing. Research in this field is limited by small sample sizes with broad patient heterogeneity. Recent Findings The mainstays of heart failure treatment include goal-directed medical therapies, electrophysiology interventions, mechanical circulatory support, and transplant. Although these therapies have been studied in the adult populations in the more traditional left-sided heart failure, data is limited in the use of these therapies in adults with congenital heart disease. Summary Collaborative guidance is needed to advance the management and care of the fast-growing population of adults with congenital heart disease.
- 5 November 2024
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 27 (1) , 1-11
Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies
Purpose of the Review The need for treatments and specialists to manage complications that adults with congenital heart disease experience with heart failure is pressing. Research in this field is limited by small sample sizes with broad patient heterogeneity. Recent Findings The mainstays of heart failure treatment include goal-directed medical therapies, electrophysiology interventions, mechanical circulatory support, and transplant. Although these therapies have been studied in the adult populations in the more traditional left-sided heart failure, data is limited in the use of these therapies in adults with congenital heart disease. Summary Collaborative guidance is needed to advance the management and care of the fast-growing population of adults with congenital heart disease.
- Open Access
- 23 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7250
Changes in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction
Background: Transthyretin cardiac amyloidosis (ATTR-CM) is classically thought of as a progressive disease with preserved systolic function. The longitudinal clinical trajectories of ATTR-CM with impaired left ventricular ejection fraction (LVEF) remain unclear. Methods: This is a single-center retrospective cohort study of consecutive patients with ATTR-CM who underwent two or more echocardiograms with baseline LVEF < 50%. Patients were stratified according to the presence of ≥5% change in LVEF. A Cox proportional hazard model examined hazard of a composite outcome of death, transplant, or LVAD insertion over the two years following diagnosis. Results: In our study cohort of 179 patients, 62 patients (34.6%) experienced an increase in LVEF while 33 (18.4%) experienced a decrease in LVEF. After adjusting for covariates, patients with a decrease in EF experienced increased hazard of death (HR 2.15, 95% CI 1.05–4.40, p = 0.038) compared to those with stable or an increase in LVEF. Changes in LVEF corresponded with significant differences in NT proBNP trajectories, but initial biomarker levels or clinical staging were not predictive of LVEF trajectory. Conclusions: in ATTR-CM patients with impaired LVEF, over a third demonstrated improved LVEF over time, while those with a decrease in LVEF had worse long-term outcomes.
- 23 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7250
Open AccessChanges in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction
Background: Transthyretin cardiac amyloidosis (ATTR-CM) is classically thought of as a progressive disease with preserved systolic function. The longitudinal clinical trajectories of ATTR-CM with impaired left ventricular ejection fraction (LVEF) remain unclear. Methods: This is a single-center retrospective cohort study of consecutive patients with ATTR-CM who underwent two or more echocardiograms with baseline LVEF < 50%. Patients were stratified according to the presence of ≥5% change in LVEF. A Cox proportional hazard model examined hazard of a composite outcome of death, transplant, or LVAD insertion over the two years following diagnosis. Results: In our study cohort of 179 patients, 62 patients (34.6%) experienced an increase in LVEF while 33 (18.4%) experienced a decrease in LVEF. After adjusting for covariates, patients with a decrease in EF experienced increased hazard of death (HR 2.15, 95% CI 1.05–4.40, p = 0.038) compared to those with stable or an increase in LVEF. Changes in LVEF corresponded with significant differences in NT proBNP trajectories, but initial biomarker levels or clinical staging were not predictive of LVEF trajectory. Conclusions: in ATTR-CM patients with impaired LVEF, over a third demonstrated improved LVEF over time, while those with a decrease in LVEF had worse long-term outcomes.
- 16 August 2023
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 20 (5) , 401-416
Novel Therapeutic Strategies in Heart Failure in Adult Congenital Heart Disease: of Medicines and Devices
Purpose of Review This paper reviews the latest literature on the growing field of heart failure in the adult congenital heart disease population. Recent Findings After highlighting the increasing prevalence and a few of the unique potential causes, including the concept of early senescence, this review begins with novel medical management strategies such as the angiotensin II receptor blocker and neprilysin inhibitors and sodium glucose cotransporter-2 inhibitors. Then, it addresses the latest applications of percutaneous techniques like implantable hemodynamic monitoring, transcatheter pulmonary and aortic valve replacement, and mitral clips. Cardiac resynchronization therapy and novel lymphatic system imaging and intervention are then described. Finally, the use of mechanical support devices, temporary and durable, is discussed as well as heart and combined heart and liver transplantation. Summary There have been recent exciting advances in the strategies used to manage adult congenital heart disease patients with heart failure. As this population continues to grow, it is likely we will see further rapid evolution in this field.
- 16 August 2023
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 20 (5) , 401-416
Novel Therapeutic Strategies in Heart Failure in Adult Congenital Heart Disease: of Medicines and Devices
Purpose of Review This paper reviews the latest literature on the growing field of heart failure in the adult congenital heart disease population. Recent Findings After highlighting the increasing prevalence and a few of the unique potential causes, including the concept of early senescence, this review begins with novel medical management strategies such as the angiotensin II receptor blocker and neprilysin inhibitors and sodium glucose cotransporter-2 inhibitors. Then, it addresses the latest applications of percutaneous techniques like implantable hemodynamic monitoring, transcatheter pulmonary and aortic valve replacement, and mitral clips. Cardiac resynchronization therapy and novel lymphatic system imaging and intervention are then described. Finally, the use of mechanical support devices, temporary and durable, is discussed as well as heart and combined heart and liver transplantation. Summary There have been recent exciting advances in the strategies used to manage adult congenital heart disease patients with heart failure. As this population continues to grow, it is likely we will see further rapid evolution in this field.
- 1 April 2023
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (4) , e009908
Predictive Modeling to Assess Pretest Probability of Transthyretin Gene Variants Based on Demographic Information
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a morbid condition, though recent advances in diagnosis and therapy stand to change its natural history. Patients’ TTR genotype may guide family screening as more treatments and preventive strategies become available. An efficient, intuitive means of determining pretest genetic risk may better inform patients/clinicians when pursuing genetic testing. Methods: This is a cohort study of 767 consecutive patients diagnosed with ATTR-CM who underwent genetic testing. Classification and regression trees (CART) analysis created a decision tree assessing likelihood of carrying a pathologic TTR gene variant. Age, sex, and race were used as independent variables. Logistic regression was also performed to model probability of pathologic TTR genotype. The primary outcome was the decision tree’s accuracy in 2 separate institutions’ ATTR-CM registry. Results: In our study cohort, 208 patients (27.1%) had ATTRv. Race has served most efficiently as the root node followed by age and sex in a CART algorithm, and showed 88.2% accuracy (75.3% sensitivity, 93.9% specificity) in the validation cohort. The odds of having a TTR gene variant were greater in Black patients compared with non-Black patients (OR, 34.6 [95% CI, 20.5–58.3]; P TTR mutations with high specificity. Non-Black patients diagnosed at age 69 years or older with ATTR-CM have a low likelihood to have ATTRv.
- 1 April 2023
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (4) , e009908
Predictive Modeling to Assess Pretest Probability of Transthyretin Gene Variants Based on Demographic Information
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a morbid condition, though recent advances in diagnosis and therapy stand to change its natural history. Patients’ TTR genotype may guide family screening as more treatments and preventive strategies become available. An efficient, intuitive means of determining pretest genetic risk may better inform patients/clinicians when pursuing genetic testing. Methods: This is a cohort study of 767 consecutive patients diagnosed with ATTR-CM who underwent genetic testing. Classification and regression trees (CART) analysis created a decision tree assessing likelihood of carrying a pathologic TTR gene variant. Age, sex, and race were used as independent variables. Logistic regression was also performed to model probability of pathologic TTR genotype. The primary outcome was the decision tree’s accuracy in 2 separate institutions’ ATTR-CM registry. Results: In our study cohort, 208 patients (27.1%) had ATTRv. Race has served most efficiently as the root node followed by age and sex in a CART algorithm, and showed 88.2% accuracy (75.3% sensitivity, 93.9% specificity) in the validation cohort. The odds of having a TTR gene variant were greater in Black patients compared with non-Black patients (OR, 34.6 [95% CI, 20.5–58.3]; P TTR mutations with high specificity. Non-Black patients diagnosed at age 69 years or older with ATTR-CM have a low likelihood to have ATTRv.